DeMelle OncoPharma

DeMelle OncoPharma was a clinical-stage oncology biotechnology company focused on developing therapies for high-unmet-need cancers, initially centered on pancreatic cancer. The company licensed technology from Moffitt Cancer Center to develop DM3001, described as a first-in-class targeted treatment against the novel cancer target Exportin-2. Public materials indicate DM3001 had been evaluated in a Phase 1b pre-surgical pancreatic cancer study and was also being explored for broader oncology applications including colorectal cancer. DeMelle positioned itself as a developer of licensed oncology technologies with internal expertise spanning drug development, manufacturing, and regulatory strategy. Florida business records indicate the LLC later became inactive.